Vistagen reports P-IIa study (n=10) results, PH15 (1.6µg) shown statistically significant improvement in reaction time vs PBO & caffeine (p<0.001) in sleep-deprived participants at midnight and 3:00 a.m. (most fatigued) with no SAEs
P-IIa study evaluating safety, efficacy & tolerability of intranasal PH15(1.6 µg multiple doses or 9.6 µg total dose) vs PBO (nasal spray or oral), or caffeine (single 400 mg oral dose 1 hr before session) in consecutive sleep deprivation sessions set apart 1wk, scheduled for 6:00 p.m., 9:00 p.m., midnight, and 3:00 a.m.
Company to further explore PH15 as new and transformative solution for shift work disorder, sleep apnea, and narcolepsy (leads to debilitating sleep deprivation and mental fatigue)
Ref: Vistagen | Image: Vistagen
Related News:- Vistagen Reports P-III Trial (PALISADE-2) Results of Fasedienol (PH94B) Nasal Spray for Social Anxiety Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
